LAPTM4B and neoplasm: However, there has been reported evidence of circulating tumor cells (CTCs) to be another contributing factor of HIF-1, MDR1 and LAPTM4B in patient’s blood (Kallergi et al., 2009; Liu et al., 2003; Robey et al., 2006).